216 results on '"Ruaño, Gualberto"'
Search Results
2. Subanalysis of the CYP-GUIDES Trial: CYP2D6 Functional Stratification and Operational Timeline Selection
3. Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications.
4. Pharmacogenomics: an Update for Child and Adolescent Psychiatry
5. Haplotype Variation and Linkage Disequilibrium in 313 Human Genes
6. PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting.
7. Complex Promoter and Coding Region β 2 -adrenergic Receptor Haplotypes Alter Receptor Expression and Predict in vivo Responsiveness
8. Comparative physiogenomic analyses of weight loss in response to 2 modes of bariatric surgery: demonstration with candidate neuropsychiatric and cardiometabolic genes
9. Ethnic variation in weight loss, but not co-morbidity remission, after laparoscopic gastric banding and Roux-en-Y gastric bypass
10. Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia
11. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
12. An Expiration Date for Pharmacogenetic Test Results and Prescribing Guidance?
13. VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders: a B-SNIP study
14. Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients
15. Prevalence of Combinatorial CYP2C9 and VKORC1 Genotypes in Puerto Ricans : Implications for Warfarin Management in Hispanics
16. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies
17. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone
18. Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecules
19. Coupled Amplification and Sequencing of Genomic DNA
20. Pharmacogenetic Testing in Psychiatry: A Review of Features and Clinical Realities
21. Physiogenomic Analysis of Localized fMRI Brain Activity in Schizophrenia
22. On naturalistic pharmacogenetic studies: reply from the authors
23. A clinical study of the association of antipsychotics with hyperlipidemia
24. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder
25. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients
26. Automated Extraction of Pain Symptoms: A Natural Language Approach using Electronic Health Records.
27. Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training
28. ‘Generic to genetic’ transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine
29. Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing
30. Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients
31. Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes
32. Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
33. Physiogenomic analysis of the Puerto Rican population
34. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach.
35. Detailed analysis of a 17q21 microdissection library by sequence bioinformatics and isolation of region-specific clones
36. Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital
37. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing
38. PHYSIOGENOMIC ASSOCIATION OF STATIN-RELATED MYALGIA TO SEROTONIN RECEPTORS
39. High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety
40. Designing physiogenomic studies
41. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis
42. Personalizing public health
43. Quo vadis personalized medicine?
44. Genomas, Inc.
45. Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies
46. Personalized health and the coronavirus vaccines—Do individual genetics matter?
47. Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat
48. Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction
49. Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service.
50. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.